On-body injector delivery of subcutaneous teprotumumab achieves clinically meaningful proptosis reduction in phase 3 thyroid eye disease study.

Mineral casts of cancer cell surfaces reprogram fat cells into stem cells and improve insulin sensitivity in obese mice ...

Amgen announces positive phase 3 results for subcutaneous Tepezza in adults living with moderate-to-severe active thyroid eye disease: Thousand Oaks, California Wednesday, April 8 ...

Drugmakers Novo Nordisk and Eli Lilly and Company have transformed the landscape of chronic weight loss management with the ...

Two Alzheimer's drugs were hailed as treatments that would transform care. Why are barely any UK patients getting them?

Primary and Key Secondary Endpoints Met 77% of Patients Achieved Highly Statistically Significant Proptosis Response Study Showed Clinically Meaningful Reduction ...

Health and wellness influencers are hawking unapproved treatments on the gray market. The future of the F.D.A.—and the health ...

Obesity is a problem not just of aesthetics or appearance; it is a chronic disease that affects the heart, increases the risk ...

The expiry of Novo Nordisk’s semaglutide patent has opened the door for generic manufacturers in the Indian market, where ...

For the past 7 years, pharmaceuticals that work as glucagon-like peptide 1 (GLP-1) receptor agonists have dominated the weight-loss and diabetes markets. These drugs, currently so ...

*A gene therapy that may eliminate, or significantly reduce, the need for daily insulin injections is preparing to enter ...

OPDIVO is a prescription medicine used in combination with YERVOY as a first treatment to treat adults with cancer of the ...